Yuhan teams up with AbClon to develop Covid treatment

Home > Business > Industry

print dictionary print

Yuhan teams up with AbClon to develop Covid treatment

A researcher is working in the lab of the pharmaceutical company Yuhan. [YUHAN]

A researcher is working in the lab of the pharmaceutical company Yuhan. [YUHAN]

 
Korea’s leading pharmaceutical company Yuhan is officially in the race to develop a Covid-19 treatment, the company announced Monday.
 
Yuhan has been the No. 1 pharmaceutical company in Korea by annual revenue for five years straight. The company said Monday that it is currently working with a smaller company, AbClon, to co-develop an antibody treatment against Covid-19.
 
A 20-year-old company specializing in antibody treatments, AbClon started developing a candidate substance targeting the respiratory disease in February this year. After narrowing down from a list of 20 candidate substances, the two companies are currently focusing on one candidate which Yuhan says showed positive effects in neutralizing the Covid-19 virus that swept Asia and the modified “G-Strain” prevalent in the United States and Europe.
 
Yuhan’s role in the collaboration would be conducting pre-clinical evaluations on the candidate substance, preparing documents for clinical trials and designing the structure and action plans of how the tests will be carried out.

 
A task force composed of staff from both companies is in charge of the development, Yuhan said. At the moment, their core focus is producing a sufficient amount of cells and samples that would be used at the pre-clinical stage and clinical tests. AbClon already has prior experience co-developing treatments with Yuhan.  
 
“At a time when the entire world is facing a crisis due to the pandemic, sharing technology and assets among industry insiders is the best way to accelerate development of a Covid-19 treatment. We will do our best to contribute to the well-being of humanity,” said Yuhan CEO and President Lee Jung-hee.

 
BY SONG KYOUNG-SON   [song.kyoungson@joongang.co.kr]

More in Industry

Korea Shipbuilding signs ₩87.5 billion deal to build LPG carrier

DMI to develop drone-based marine charting system

Graft regulations eased to allow for more expensive gifts

Hanwha is first Rolls-Royce supplier permitted to handle quality control

Live commerce, perfect for the pandemic, is all the rage

Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now